COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease

Area of Science:

• Rheumatology
• Immunology
• Infectious Diseases

Background:

• The COVID-19 pandemic presents unique challenges for patients with autoimmune rheumatic diseases like systemic lupus erythematosus (SLE).
• Patients with SLE may have increased susceptibility to SARS-CoV-2 infection and altered disease outcomes due to immunosuppressive therapies and inherent disease mechanisms.
• Type I interferon activity, common in SLE, could influence COVID-19 pathogenesis, potentially offering antiviral defense or exacerbating hyperinflammation.

Purpose of the Study:

• To review the current literature on COVID-19 in patients with SLE.
• To analyze the impact of COVID-19 on SLE patients, considering epidemiological, clinical, and immunological aspects.
• To explore the psychosocial effects of the pandemic on individuals with autoimmune diseases.

Main Methods:

• Comprehensive literature search of studies on COVID-19 in SLE patients.
• Review of data on immune pathway activation, epidemiology, clinical features, and outcomes.
• Inclusion of research on the psychosocial impact of the pandemic on autoimmune disease populations.

Main Results:

• SLE patients present distinct risk factors for COVID-19 acquisition and severity.
• Immunopathogenic pathways in SLE may overlap with those in severe COVID-19, offering insights into hyperinflammation.
• Systemic glucocorticoid and immunosuppressant use in SLE can influence infection risk and outcomes.

Conclusions:

• COVID-19 significantly impacts patients with SLE, necessitating careful management and monitoring.
• Research into SLE immune responses provides valuable perspectives on SARS-CoV-2 infection mechanisms.
• Further studies are crucial to understand and mitigate the combined effects of SLE and COVID-19.